Results 111 to 120 of about 2,160 (157)

Molecular dynamics simulation and single-cell and spatial transcriptomics validate immune and prognostic biomarkers in colorectal cancer and construct a clinical prognostic model. [PDF]

Transl Cancer Res
Chen X, Zhou Y, Li H, Guo W, Li S, Zhang Z, Tang Q.   +6 more
europepmc   +1 more source

1392 EVOLVE-104, a novel ULBP2-targeted T cell engager that integrates CD2 costimulation for the treatment of basal and squamous lineage tumors

Journal for ImmunoTherapy of Cancer, 2023
Jay S Fine, Louis Matis, Stella Martomo, Xingyue An, Mohosin Sarkar, Abudukadier Abulizi, Guixian Jin, Evelyn Teran, Danielle Klaskin, Maria Hackett, Hayden Karp, Julio Rodriguez, Sonali Dhindwal, Changqing Yuan, Zengzu Lai, Jennifer Zeiger, Amber Fearnley, Oksana A Sergeeva, Eric M Tam, Tracy Lichter, Jeremy S Myers   +20 more
doaj   +1 more source

Causal effects of plasma protein-protein ratios on lung cancer subtypes: A proteome-wide Mendelian randomization and mediation analysis. [PDF]

Medicine (Baltimore)
Geng X, Xue J, Liu K, Song Z, Wang Y, Cao X, Li Z, Chen L.   +7 more
europepmc   +1 more source

Targeting NKG2D/NKG2DL axis in cancer immunotherapy: mechanisms and therapeutic applications. [PDF]

J Transl Med
Wei H, Xiang L, Zhou Y, Huang Y, Liu L, Cao D.   +5 more
europepmc   +1 more source

NKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions. [PDF]

Front Immunol
Liu C, Wang Z, Zhang W, Cheng G, Cheng S, Qin L, Ye H, Ren W.   +7 more
europepmc   +1 more source

Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

Frontiers in Immunology, 2018
Stephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, Tanja Gardlowski, Nadine Matthies, Maulik Vyas, Lubomir Arseniev, Michael Heuser, Elke Pogge von Strandmann, Ulrike Köhl   +9 more
doaj   +1 more source

Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancreatic cancer. [PDF]

J Biol Eng
Lee SG, Lee M, Lee HM, Son GH, Yoon SR, Chae BH, Kim DS, Lee KM, Kim YS.   +8 more
europepmc   +1 more source

[Research progress of the ULBP-NKG2D axis in autoimmune diseases]. [PDF]

Zhejiang Da Xue Xue Bao Yi Xue Ban
Ma J, Wu J, Jin Y.
europepmc   +1 more source

Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy. [PDF]

Immunotherapy
Mazzaschi G, Rosati R, D'Agnelli S, Minari R, Trentini F, Tamarozzi P, Manini M, Zinelli Ronzoni M, Dodi A, Gnetti L, Bottarelli L, Azzoni C, Martines G, Pluchino M, Toscani I, Leonetti A, Perrone F, Bordi P, Bocchialini G, Ampollini L, Quaini F, Tiseo M.   +21 more
europepmc   +1 more source

Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells. [PDF]

Mol Pharm
Gondaliya P, Zinn DA, Sayyed AA, Driscoll J, Yan IK, Mensali N, Wälchli S, Patel T.   +7 more
europepmc   +1 more source